DiaMedica Therapeutics Inc. DMAC
9.76 USD +0.40 (+4.33%)
Nov 9, 2026, 10:32 AM EST
9.42 Day range 9.78
5.25 52-week range 11.00
- YTD
- +22.67%
- 1 year
- +64.95%
News
businesswire.com DiaMedica Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Business Update November 13, 2026 MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction…
benzinga.com DiaMedica Therapeutics Enrolls 200th Patient In ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial Independent Data Safety Monitoring Board to Conduct a Pre-Specified Interim Analysis to Assess Need for Sample Size Re-EstimationInterim Analysis Results Expected in Q1 2027
benzinga.com HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and maintains $12 price target.
benzinga.com DiaMedica Therapeutics Q2 EPS $(0.19) Beats $(0.20) Estimate DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 5.56 percent decrease over losses of…
benzinga.com Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrollment of first patient in phase 3 trial.
benzinga.com DiaMedica Therapeutics Doses First Patients In Its Phase 2 Trial Of DM199 For The Treatment Of Fetal Growth Restriction First clinical evaluation of DM199 (rinvecalinase alfa) in fetal growth restriction, a leading cause of stillbirth with no approved pharmacologic treatmentDM199 is intended to improve maternal…
benzinga.com DiaMedica Receives FDA Written Response About The Need For Additional Nonclinical Reproductive Toxicity Data To Support Continued Development Of DM199 For The Treatment Of Preeclampsia DiaMedica believes, based on the FDA's feedback, that the previously completed rat reproductive toxicity study may be acceptable to support a U.S. investigational new drug (IND) application, provided…- benzinga.com DiaMedica Therapeutics Announces 75% Enrollment In Its Phase 2/3 ReMEDy2 trial of DM199 In Patients With Acute Ischemic Stroke ReMEDy2 Phase 2/3 AIS Trial of DM199 Surpasses 75% of Enrollment Required to Trigger Pre-Specified Interim AnalysisInterim Analysis by Independent DSMB Expected to Determine if a Sample Size…
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com DiaMedica Therapeutics Q1 EPS $(0.19), Inline DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.19) per share which met the analyst consensus estimate. This is a 5.56 percent decrease over losses of $(0.18) per share from the…
- benzinga.com Earnings Scheduled For March 30, 2026
benzinga.com Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings DiaMedica Therapeutics (NASDAQ: DMAC) will release Q4 earnings on March 30. Analysts expect a quarterly loss of 18 cents per share. Stock fell 0.9% on Friday.- benzinga.com DiaMedica Therapeutics Gets No Objection Letter From Health Canada For Its Clinical Study Application Of DM199 In Phase 2 Trial In Participants With Early-Onset Preeclampsia DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke…
benzinga.com DiaMedica Therapeutics Completes Productive In-Person Pre-IND Meeting With FDA For Planned Study Evaluating DM199 In Preeclampsia DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com Cantor Fitzgerald Initiates Coverage On DiaMedica Therapeutics with Overweight Rating, Announces Price Target of $25 Cantor Fitzgerald analyst Josh Schimmer initiates coverage on DiaMedica Therapeutics (NASDAQ:DMAC) with a Overweight rating and announces Price Target of $25.
- benzinga.com DiaMedica Therapeutics Q3 EPS $(0.17), Inline DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.17) per share which met the analyst consensus estimate. This is a 13.33 percent decrease over losses of $(0.15) per share from…
- benzinga.com Earnings Scheduled For November 12, 2025
benzinga.com An Overview of DiaMedica Therapeutics's Earnings 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and maintains $12 price target.
benzinga.com DiaMedica Therapeutics Q2 EPS $(0.18) Beats $(0.19) Estimate DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 38.46 percent decrease over losses…- benzinga.com Earnings Scheduled For August 12, 2025
- benzinga.com Exploring DiaMedica Therapeutics's Earnings Expectations
- benzinga.com Craig-Hallum Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $11 Craig-Hallum analyst Chase Knickerbocker maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and raises the price target from $8 to $11.
- benzinga.com Lake Street Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $14 Lake Street analyst Thomas Flaten maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and raises the price target from $11 to $14.
- benzinga.com HC Wainwright & Co. Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $12 HC Wainwright & Co. analyst Matthew Caufield maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and raises the price target from $10 to $12.
- benzinga.com DiaMedica Therapeutics Announces Interim Results From Part 1a Of Phase 2 Study Of DM199 For Treatment Of Preeclampsia Conference Call Today July 17, 2025 at 4:30 PM Eastern Time / 3:30 PM Central TimeDM199 Demonstrated Highly Statistically Significant and Clinically Meaningful Reductions in Systolic and Diastolic…
benzinga.com HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $10 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and maintains $10 price target.
benzinga.com DiaMedica Therapeutics Announces Key Opinion Leader Webinar On DM199 For The Treatment Of Preeclampsia On Wednesday, May 28, 2025, At 8:00 AM ET Company to Host Preeclampsia Key Opinion Leader Event May 28, 2025 at 8 AM Eastern / 7 AM CentralDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on…- benzinga.com DiaMedica Therapeutics Q1 EPS $(0.18), Inline DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.18) per share which met the analyst consensus estimate. This is a 28.57 percent decrease over losses of $(0.14) per share from…
- benzinga.com Earnings Scheduled For May 13, 2025
- benzinga.com Insights Ahead: DiaMedica Therapeutics's Quarterly Earnings
benzinga.com Why Ericsson Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - benzinga.com HC Wainwright & Co. Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $10 HC Wainwright & Co. analyst Matthew Caufield maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and raises the price target from $7 to $10.
- benzinga.com DiaMedica Therapeutics FY 2024 GAAP EPS $(0.60) Misses $(0.59) Estimate DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.59) by 1.69 percent.
- benzinga.com Earnings Scheduled For March 17, 2025
- benzinga.com HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $7 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and maintains $7 price target.
- benzinga.com DiaMedica Therapeutics Q3 2024 GAAP EPS $(0.15), Inline DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate.
- benzinga.com Earnings Scheduled For November 13, 2024
- benzinga.com Preview: DiaMedica Therapeutics's Earnings
- benzinga.com HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $7 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and maintains $7 price target.
- benzinga.com This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
- benzinga.com HC Wainwright & Co. Initiates Coverage On DiaMedica Therapeutics with Buy Rating, Announces Price Target of $7 HC Wainwright & Co. analyst Matthew Caufield initiates coverage on DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy rating and announces Price Target of $7.
- benzinga.com Oppenheimer Reiterates Outperform on DiaMedica Therapeutics, Maintains $6 Price Target Oppenheimer analyst Francois Brisebois reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Outperform and maintains $6 price target.
- benzinga.com DiaMedica Therapeutics Q2 2024 GAAP EPS $(0.13) Beats $(0.16) Estimate DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.16) by 18.75 percent.
- benzinga.com DiaMedica Therapeutics Releases Preeclampsia White Paper And Announces Key Opinion Leader Webinar On DM199 For The Treatment Of Preeclampsia Company to Host Preeclampsia Key Opinion Leader Event July 29, 2024 at 10 AM Eastern / 9 AM CentralWhite Paper: The Potential of DM199 to Treat PreeclampsiaDiaMedica Therapeutics Inc. (NASDAQ:DMAC),…
- benzinga.com DiaMedica Therapeutics Announces $11.8M Private Placement, Will Issue A Total Of 4.72M Common Shares At A Purchase Price Of $2.50 Per Share DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it has entered into…